We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Vicotex

Download Mobile App




Expanded Newborn Screening Program Increases Detection of Congenital Cytomegalovirus

By LabMedica International staff writers
Posted on 22 Sep 2026

Congenital cytomegalovirus is the most common maternal–fetal infection and often goes undetected at birth, despite its potential to cause progressive hearing loss and developmental delays. More...

In the United States, newborn testing is typically prompted by failed hearing screens, symptoms, or maternal concerns, leaving many infections unidentified. Screening practices also vary widely as states and hospitals adopt different policies without unified guidance. A new study now shows that a system-wide newborn screening program substantially increased detection of congenital cytomegalovirus.

Cleveland Clinic Children’s has implemented an expanded newborn screening program for congenital cytomegalovirus (cCMV) across its Ohio locations to identify infected infants earlier in routine care. The initiative, introduced between 2022 and 2025 in newborn nurseries and neonatal intensive care units (NICUs), begins with a swab-based screening test followed, when indicated, by confirmatory urine testing. Findings from the program were published in Pediatrics on September 21, 2026.

During the implementation period, more than 50,000 babies were born at Cleveland Clinic facilities, with nearly 7,500 receiving cCMV screening. Annual testing volume increased from approximately 150 infants per year to more than 2,000. The expanded program identified 34 infants with cCMV, representing about a 2.5-fold increase in detection compared with previous practice.

cCMV screening is not currently universal for all newborns in the United States and is more commonly performed after a failed hearing screen, in symptomatic infants, or when maternal complications raise concern. However, according to the National Institutes of Health, more than 40% of children who later develop cCMV-related hearing loss initially pass their newborn hearing screen. These findings have been cited in support of broader screening approaches that do not rely solely on hearing status.

“Our findings show that this screening is practical and effective. Identifying affected babies earlier allows for monitoring and ultimately treatment, helping to improve long-term outcomes,” said Frank Esper, M.D., senior author and pediatric infectious disease specialist at Cleveland Clinic Children's.

Related Links
Cleveland Clinic Children's


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Aspiration System
VACUSAFE
New
Microbiology Laboratory Automation Solution
BD Kiestra™ ReadA+BarcodA
All-in-One Molecular System
AIO M160
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image Credit: Shutterstock

Blood Test Could Guide Drug Selection to Prevent Repeat Heart Attacks and Strokes

Secondary prevention after myocardial infarction or stroke relies on antiplatelet therapy, yet responses vary widely and both recurrent thrombosis and bleeding remain persistent risks. In the United Kingdom,... Read more

Molecular Diagnostics

view channel
Image: Signatera uses ctDNA analysis to identify residual tumor-derived genetic material after definitive treatment (image credit: Adobe Stock)

Blood-Based MRD Test Predicts Recurrence Risk After Lung Cancer Surgery

Assessing recurrence risk after surgery for early-stage non-small cell lung cancer remains challenging, complicating adjuvant therapy and surveillance decisions. Blood-based molecular residual disease... Read more

Immunology

view channel
Image: Although many people harbor latent Epstein-Barr virus (EBV), growing evidence has linked the virus to MS pathobiology (Image Credit: Adobe Stock)

Blood EBV Activity Biomarkers May Predict Multiple Sclerosis Relapse Months Ahead

Predicting relapse in multiple sclerosis (MS) remains difficult, limiting opportunities for timely intervention and monitoring. Although many people harbor latent Epstein-Barr virus (EBV), growing evidence... Read more

Pathology

view channel
Image: A new study demonstrates that vascular features in colorectal tumors could serve as prognostic biomarkers of disease outcome. (Image Credit: iStock)

Tumor Blood Vessel Features May Help Predict Colorectal Cancer Survival

Colorectal cancer outcomes vary widely, and tumor biology remains a key determinant of prognosis. Because neoplasms depend on a vascular supply, differences in intratumoral vessels may influence survival.... Read more

Technology

view channel
Image: ADLM recommends that emerging AI tools follow the same professional oversight, quality, validation, and monitoring standards as traditional clinical testing within CLIA’s existing framework (Image Credit: Adobe Stock)

ADLM Calls for CLIA Updates to Support Safe AI Use in Laboratory Medicine

Clinical laboratories increasingly use artificial intelligence to verify, interpret, and report results, but safeguards under the Clinical Laboratory Improvement Amendments (CLIA) were designed in 1992.... Read more

Industry

view channel
Image: Central to the collaboration is the Enhanced Liver Fibrosis (ELF) test, a noninvasive blood test authorized in the U.S. to assess disease progression risk in patients with advanced fibrosis due to MASH and support patient management decisions. (Photo courtesy of Siemens Healthineers)

Siemens Healthineers and Novo Collaborate to Expand Access to Noninvasive Liver Testing

Metabolic dysfunction‑associated steatotic liver disease (MASLD) and its progressive form, metabolic dysfunction‑associated steatohepatitis (MASH), affect millions and are linked to obesity, type 2 diabetes,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.